Go Pro
NASDAQ:ENGN

enGene Q2 2025 Earnings Report

enGene logo
$1.80 +0.04 (+1.98%)
As of 02:35 PM Eastern
This is a fair market value price provided by Massive. Learn more.

enGene EPS Results

Actual EPS
-$0.51
Consensus EPS
-$0.48
Beat/Miss
Missed by -$0.03
One Year Ago EPS
N/A

enGene Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

enGene Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Thursday, June 12, 2025
Conference Call Time
8:00AM ET

Upcoming Earnings

enGene's Q3 2026 earnings is estimated for Monday, September 14, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, September 9, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

enGene Earnings Headlines

Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.tc pixel
5 Toyota engines you should steer clear of
See More enGene Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like enGene? Sign up for Earnings360's daily newsletter to receive timely earnings updates on enGene and other key companies, straight to your email.

About enGene

enGene (NASDAQ:ENGN) is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs. enGene’s lead program is detalimogene voraplasmid (also known as detalimogene, and previously EG-70) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. Detalimogene was developed using enGene’s proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA.

View enGene Profile